(Latanoprost + netarsudil mesylate) is a Small Molecule owned by Aerie Pharmaceuticals, and is involved in 5 clinical trials, of which 4 were completed, and 1 is ongoing.

AR-13324 inhibits both Rho Kinase (ROCK) and the Norepinephrine Transporter (NET) which increases fluid outflow and reduces fluid inflow. ROCK is a type of protein kinase that regulates actin and myosin which are proteins that are responsible for cellular contraction. In the trabecular outflow pathway of the eye, the resistance to fluid outflow that maintains normal intraocular pressure (IOP) is regulated by the contraction of trabecular meshwork (TM) cells and the production of extracellular matrix. ROCK inhibitors block TM cell contraction and reduce the production of extracellular matrix, thereby increasing fluid outflow and thus decreasing IOP. Latanoprost is a prostanoid selective FP receptor agonist that reduces the IOP by increasing the outflow of aqueous humor.

The revenue for (Latanoprost + netarsudil mesylate) is expected to reach a total of $116m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the (Latanoprost + netarsudil mesylate) NPV Report.

(Latanoprost + netarsudil mesylate) is currently owned by Aerie Pharmaceuticals. Santen Pharmaceutical is the other company associated in development or marketing of (Latanoprost + netarsudil mesylate).

(Latanoprost + netarsudil mesylate) Overview

Latanoprost and Netarsudil mesylate (Rocklatan/ Roclanda) is a fixed dose combination, acts as an anti-glaucoma agent. It is formulated as solution drops for ophthalmic route of administration. Rocklatan is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

It is under development for the reduction of intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. Netarsudil (AR-13324) acts by targeting both Rho kinase (ROCK) and the norepinephrine transporter (NET). Latanoprost acts by prostaglandin F receptor (FP receptor).

Santen Pharmaceutical Overview

Santen Pharmaceutical (Santen) focuses on the research, development, manufacturing and marketing of pharmaceutical products and medical devices. Its product portfolio includes prescription ophthalmic products for glaucoma, bacterial conjunctivitis, dry eye, inflammation, cataract, muscae volitantes, diabetic retinopathy, retinal detachment, hyposphagma, myopia, retinal detachment, amblyopia, astigmatism, strabismus, hordeolum, VDT syndrome and others; over-the-counter products ophthalmic products; anti-allergy ophthalmic products; and medical devices such as intraocular lenses (IOLs) and other ophthalmic products. Santen operates through its group companies located in Asia, Europe and the US. It operates production facilities in Noto, and Shiga, Japan; and Suzhou, China. Santen is headquartered in Kita-ku, Osaka, Japan.

The company reported revenues of (Yen) JPY266,257 million for the fiscal year ended March 2022 (FY2022), an increase of 6.7% over FY2021. In FY2022, the company’s operating margin was 14%, compared to an operating margin of 4.9% in FY2021. In FY2022, the company recorded a net margin of 10.2%, compared to a net margin of 3.7% in FY2021. The company reported revenues of JPY63,382 million for the second quarter ended September 2022, a decrease of 3.3% over the previous quarter.

Quick View – (Latanoprost + netarsudil mesylate)

Report Segments
  • Innovator (Non-NME)
Drug Name
  • (Latanoprost + netarsudil mesylate)
Administration Pathway
  • Ophthalmic
Therapeutic Areas
  • Ophthalmology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.